Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3049% below fair value
$149.40−7.10 (-4.54%)
Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –
Alnylam Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Alnylam Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $977.59M, up 269.3% year over year. For fiscal 2025 it was $501.58M. The highest annual figure on record is $501.58M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $501.58M | – |
| FY2024 | Dec 31, 2024 | -$176.89M | – |
| FY2023 | Dec 31, 2023 | -$282.18M | – |
| FY2022 | Dec 31, 2022 | -$785.07M | – |
| FY2021 | Dec 31, 2021 | -$708.65M | – |
| FY2020 | Dec 31, 2020 | -$828.44M | – |
| FY2019 | Dec 31, 2019 | -$939.43M | – |
| FY2018 | Dec 31, 2018 | -$814.67M | – |
| FY2017 | Dec 31, 2017 | -$500.09M | – |
| FY2016 | Dec 31, 2016 | -$424.59M | – |
| FY2015 | Dec 31, 2015 | -$296.01M | – |
| FY2014 | Dec 31, 2014 | -$404.98M | – |
| FY2013 | Dec 31, 2013 | -$92.94M | – |
| FY2012 | Dec 31, 2012 | -$129.46M | – |
| FY2011 | Dec 31, 2011 | -$54.82M | – |
| FY2010 | Dec 31, 2010 | -$44.07M | – |
| FY2009 | Dec 31, 2009 | -$48.11M | – |
| FY2008 | Dec 31, 2008 | -$27.84M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $345.80M | -6.0% |
| Q2 FY2026 | Jun 30, 2026 | $231.44M | – |
| Q1 FY2026 | Mar 31, 2026 | $268.64M | +1386.1% |
| Q4 FY2025 | Dec 31, 2025 | $131.72M | – |
| Q3 FY2025 | Sep 30, 2025 | $367.98M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.20M | -133.3% |
| Q1 FY2025 | Mar 31, 2025 | $18.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$105.16M | – |
| Q3 FY2024 | Sep 30, 2024 | -$76.91M | -136.0% |
| Q2 FY2024 | Jun 30, 2024 | $48.61M | – |
| Q1 FY2024 | Mar 31, 2024 | -$43.44M | – |
| Q4 FY2023 | Dec 31, 2023 | -$116.40M | – |
| Q3 FY2023 | Sep 30, 2023 | $213.87M | – |
| Q2 FY2023 | Jun 30, 2023 | -$229.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$149.81M | – |
| Q4 FY2022 | Dec 31, 2022 | -$188.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$258.04M | – |
| Q2 FY2022 | Jun 30, 2022 | -$191.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$146.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$194.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$181.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$146.16M | – |
| Q1 FY2021 | Mar 31, 2021 | -$186.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$194.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$225.20M | – |
| Q2 FY2020 | Jun 30, 2020 | -$198.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$210.16M | – |
| Q4 FY2019 | Dec 31, 2019 | -$298.07M | – |
| Q3 FY2019 | Sep 30, 2019 | -$216.30M | – |
| Q2 FY2019 | Jun 30, 2019 | -$236.27M | – |
| Q1 FY2019 | Mar 31, 2019 | -$188.79M | – |
| Q4 FY2018 | Dec 31, 2018 | -$220.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$254.56M | – |
| Q2 FY2018 | Jun 30, 2018 | -$192.35M | – |
| Q1 FY2018 | Mar 31, 2018 | -$147.41M | – |
| Q4 FY2017 | Dec 31, 2017 | -$147.30M | – |
| Q3 FY2017 | Sep 30, 2017 | -$125.80M | – |
| Q2 FY2017 | Jun 30, 2017 | -$120.47M | – |
| Q1 FY2017 | Mar 31, 2017 | -$106.51M | – |
| Q4 FY2016 | Dec 31, 2016 | -$115.43M | – |
See a number that looks wrong?